Pregnancy outcomes during treatment with interferon beta-1a in patients with multiple sclerosis

DOI Web Site 被引用文献1件
  • M. Sandberg-Wollheim
    From the Department of Neurology (Dr. Sandberg-Wollheim), University Hospital, Lund, Sweden; Serono, Inc. (Drs. Lopez-Bresnahan, Chang, and Francis, D. Frank), Rockland, MA; Serono (M. Stam-Moraga), Geneva, Switzerland; Department of Obstetrics and Gynecology (Dr. Goodwin), University of Southern California; and Department of Neurology (Dr. Giesser), University of California, Los Angeles.
  • D. Frank
    From the Department of Neurology (Dr. Sandberg-Wollheim), University Hospital, Lund, Sweden; Serono, Inc. (Drs. Lopez-Bresnahan, Chang, and Francis, D. Frank), Rockland, MA; Serono (M. Stam-Moraga), Geneva, Switzerland; Department of Obstetrics and Gynecology (Dr. Goodwin), University of Southern California; and Department of Neurology (Dr. Giesser), University of California, Los Angeles.
  • T. M. Goodwin
    From the Department of Neurology (Dr. Sandberg-Wollheim), University Hospital, Lund, Sweden; Serono, Inc. (Drs. Lopez-Bresnahan, Chang, and Francis, D. Frank), Rockland, MA; Serono (M. Stam-Moraga), Geneva, Switzerland; Department of Obstetrics and Gynecology (Dr. Goodwin), University of Southern California; and Department of Neurology (Dr. Giesser), University of California, Los Angeles.
  • B. Giesser
    From the Department of Neurology (Dr. Sandberg-Wollheim), University Hospital, Lund, Sweden; Serono, Inc. (Drs. Lopez-Bresnahan, Chang, and Francis, D. Frank), Rockland, MA; Serono (M. Stam-Moraga), Geneva, Switzerland; Department of Obstetrics and Gynecology (Dr. Goodwin), University of Southern California; and Department of Neurology (Dr. Giesser), University of California, Los Angeles.
  • M. Lopez-Bresnahan
    From the Department of Neurology (Dr. Sandberg-Wollheim), University Hospital, Lund, Sweden; Serono, Inc. (Drs. Lopez-Bresnahan, Chang, and Francis, D. Frank), Rockland, MA; Serono (M. Stam-Moraga), Geneva, Switzerland; Department of Obstetrics and Gynecology (Dr. Goodwin), University of Southern California; and Department of Neurology (Dr. Giesser), University of California, Los Angeles.
  • M. Stam-Moraga
    From the Department of Neurology (Dr. Sandberg-Wollheim), University Hospital, Lund, Sweden; Serono, Inc. (Drs. Lopez-Bresnahan, Chang, and Francis, D. Frank), Rockland, MA; Serono (M. Stam-Moraga), Geneva, Switzerland; Department of Obstetrics and Gynecology (Dr. Goodwin), University of Southern California; and Department of Neurology (Dr. Giesser), University of California, Los Angeles.
  • P. Chang
    From the Department of Neurology (Dr. Sandberg-Wollheim), University Hospital, Lund, Sweden; Serono, Inc. (Drs. Lopez-Bresnahan, Chang, and Francis, D. Frank), Rockland, MA; Serono (M. Stam-Moraga), Geneva, Switzerland; Department of Obstetrics and Gynecology (Dr. Goodwin), University of Southern California; and Department of Neurology (Dr. Giesser), University of California, Los Angeles.
  • G. S. Francis
    From the Department of Neurology (Dr. Sandberg-Wollheim), University Hospital, Lund, Sweden; Serono, Inc. (Drs. Lopez-Bresnahan, Chang, and Francis, D. Frank), Rockland, MA; Serono (M. Stam-Moraga), Geneva, Switzerland; Department of Obstetrics and Gynecology (Dr. Goodwin), University of Southern California; and Department of Neurology (Dr. Giesser), University of California, Los Angeles.

書誌事項

公開日
2005-09-27
DOI
  • 10.1212/01.wnl.0000168905.97207.d0
公開者
Ovid Technologies (Wolters Kluwer Health)

この論文をさがす

説明

Background: Although patients with multiple sclerosis (MS) are advised to stop interferon (IFN) beta-1a therapy before becoming pregnant, some patients become pregnant while on treatment. Methods: We examined individual patient data from eight clinical trials with IFNβ-1a. Results: Of 3,361 women in the studies, 69 pregnancies were reported, of which 41 were patients receiving (or who had stopped receiving within 2 weeks prior to conception) IFNβ-1a (in utero exposure group), 22 were patients who discontinued IFNβ-1a treatment more than 2 weeks before conception (previous exposure group), and six were patients receiving placebo. The 41 in utero exposure pregnancies resulted in 20 healthy full-term infants, one healthy premature infant, nine induced abortions, eight spontaneous abortions, one fetal death, and one congenital anomaly (hydrocephalus). One patient was lost to follow-up. The 22 previous exposure pregnancies resulted in 20 full-term healthy infants, one healthy premature infant, and one birth-related congenital anomaly (Erb palsy) Conclusions: The majority (21/31) of pregnancies that had the potential to go to full term produced healthy infants. The rate of spontaneous abortion was higher, but not significantly so, in the in utero exposure group compared to general population estimates. Until more exposure data become available, patients remain advised to stop IFNβ therapy before becoming pregnant.

収録刊行物

  • Neurology

    Neurology 65 (6), 802-806, 2005-09-27

    Ovid Technologies (Wolters Kluwer Health)

被引用文献 (1)*注記

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ